RenovoCyte enters strategic partnership with VetCell to use stem cell therapy and Wellness Banking
VetCell Americas also acquired an agreement from RenovoCyte, LLC to carry RenovoCyte's equine intravenous stem cell product, Autocell-EQ. RenovoCyte's innovative stem cell technology allows intravenous treatments of exercise induced pulmonary hemorrhage (bleeders), rhabdomyolysis (tying up) and osteoarthritis in the horse. RenovoCyte Cellular Medicine Laboratories in the U.S. isolates multipotent stem cells from innovative sources such as the wolf teeth, skin biopsies, placenta and testes then cryopreserves the sample using their Wellness BankingTM protocol or cultures the cells to a known dose for autologous intravenous therapy.
"We are excited to partner with VetCell in order to help apply their equine products to U.S. customers. VetCell's experience, reputation, and success in the European market allow us to start with a very stable technology platform." said Dr. Shelly Zacharias, DVM, Director of Veterinary Operations for RenovoCyte, LLC.
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.